• Innogen Pharmaceuticals’ Suzhou plant for efsubaglutide alfa received an ANVISA-issued GMP certificate under PIC/S standards.
• Certification supports registration and market access in Brazil, a key hub for expansion into other PIC/S-aligned emerging markets.
• Efsubaglutide alfa is approved in mainland China and Macau for adult type 2 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN18616) on August 04, 2026, and is solely responsible for the information contained therein.